USFDA approves AstraZeneca’s Bydureon® Pen For Adults with Type 2 Diabetes

AstraZeneca PLC (NYSE:AZN) announced that the USFDA has approved the BYDUREON® Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

As quoted in the press release:

BYDUREON is the first and only once-weekly medicine for adults with type 2 diabetes. The BYDUREON Pen is a pre-filled, single-use pen injector, eliminating the need for the patient to transfer the medication between a vial and syringe during the self-injection process. The BYDUREON Pen contains the same formulation and dose as the original BYDUREON single-dose tray, providing the same continuous release of exenatide.

Click here to read the AstraZeneca PLC (NYSE:AZN) press release